Disease landscape
Prostate Cancer
The report identified moderate limitations in access to the diagnosis and treatment of prostate cancer in the Visegrad Group (V4) countries. The overall GAP index scores are comparable between the countries analyzed, with a difference of approximately 9 points between countries. Variations in GAP results are primarily driven by differences in access to reimbursement for the medicines included in the analysis.
Cross-Country
General GAP for Prostate Cancer
Compliance with guidelines
Of the 9 drugs recommended by the clinical practice guidelines, 8 are available in Poland, 6 in the Czech Republic and Hungary, and 4 in Slovakia, indicating a wide variation in access to the latest authorized drugs in these countries.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
Selected novel drugs*
*Erleada, Nubeqa, enzalutamide, abiraterone.
Drug access
Number of patients treated (2024)
Drug access
Population treated (%) - selected drugs*
*percentage of the population potentially eligible for treatment with selected drugs: Erleada, Nubeqa, enzalutamide, abiraterone.
Main issues
- The average time to reimbursement for prostate cancer drugs in the V4 countries is 3.1 years. The difference between the shortest and the longest mean time to reimbursement among the countries is 2.0 years.
- The proportion of patients in the target population treated with the selected novel drugs in V4 countries varies substantially with 46-56% of potentially eligible patients treated with these options in Czechia and Poland and about 85% in Hungary and Slovakia.
- All V4 states have a significant population burden in prostate cancer. The burden measured by DALYs (disability adjusted life-years) in these countries is however lower than the EU average.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).
Downloads
Prostate Cancer
Key facts
Prostate Cancer
Report for specialists
PowerBI 2026
Prostate Cancer
Report for specialists
PowerBI 2025
Prostate Cancer
Report for specialists
PowerBI 2024
Prostate Cancer
Report for specialists
PowerBI 2023
Prostate Cancer
Report for specialists
PowerBI 2022